Tools for Practice Outils pour la pratique


#235 Toxins for Health? Botulinum toxin for migraine


CLINICAL QUESTION
QUESTION CLINIQUE
What is the efficacy of botulinum toxin for migraine prophylaxis?


BOTTOM LINE
RÉSULTAT FINAL
Patients with chronic migraine who receive botulinum toxin (example Botox™) have 2 fewer migraine days per month compared to placebo (from 19 days to 11 days with treatment versus 13 days with placebo), with no benefit in episodic migraine. Adverse events include blepharoptosis, muscle weakness, neck/injection site pain and 3% stop treatment due to adverse events.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Systematic review of 28 double-blind, randomized, controlled trials (RCTs); 4190 patients with chronic or episodic migraine; mean age 42, 85% female, baseline number of headache days/month 19.1 Follow-up 4 weeks (single treatment) to 9 months:  
  • Versus placebo: 
    • Number of headache days per month:  
      • Chronic migraine (based on 2 largest RCTs):2,3 from 19 days at baseline to 11 versus 13 (placebo), mean difference 1.9. 
    • Headache severity lower with treatment by ~3 points on 10-point scale. 
    • Other outcomes (migraine duration, migraine attacks per month, proportion with ≥50% reduction in migraine attacks or days): no difference. 
    • Subgroup analysis of episodic migraines: no difference in migraine frequency or number of attacks. 
    • Adverse events:  
      • Blepharoptosis: 7.5% versus 0.5% placebo, number needed to harm (NNH)=14. 
      • Muscle weakness: 13.4% versus 0.6% placebo, NNH=7. 
      • Neck or injection site pain: NNH=11 or 40, respectively. 
      • Stopping for adverse effects (4 RCTs): 3% versus 0.8%, NNH=45. 
Versus topiramate or valproate: 
  • Number of headache days per month: no difference. 
  • Withdrawal due to adverse effects: 6.7% versus 27.1% topiramate/valproate, NNT=5. 
Limitations: Most RCTs industry sponsored, ~63-70% of patients in the 2 largest RCTs may have had medication overuse headache2,3, multiple outcomes reported.  Other systematic reviews found similar.4,5  Context: 
  • Chronic migraine defined as ≥15 headache days/month (with at least 8 migraine days).1 
  • Botulinum toxin does not reduce number of chronic tension-type headaches.5 
  • Adverse effects generally transient but can last a few months.6 
  • Botox™ RCT dose 155-195 total units, delivered as 5-unit (0.1 ml) injections at 31-39 sites.2,3 
    • Cost ~$800 every 3 months. 
  • Guidelines suggest use7 in chronic migraine after failure of 2-3 prophylactic agents.8 


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Adrienne J Lindblad BSP ACPR PharmD
  • Paul Fritsch MD

1. Herd CP, Tomlinson CL, Rick C, et al. Cochrane Database System Rev. 2018; 6:CD011616.

2. Aurora SK, Dodick DW, Turkel CC, et al. Cephalalgia. 2010; 30(7):793-803.

3. Diener HC, Dodick DW, Aurora SK, et al. Cephalalgia. 2010; 30(7):804-14.

4. Bruloy E, Sinna R, Grolleau JL, et al. Plast Recontr Surg. 2019; 143:239-250.

5. Jackson JL, Kuriyama A, Hayashino Y. JAMA. 2012; 307(16):1736-45.

6. Botox™ (onabotulinumtoxinA) [product monograph]. Markham, ON: Allergan, Inc; 2014. Available at: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/botox-pm-2014-07-07_e.pdf Accessed April 4, 2019.

7. Simpson DM, Hallett M, Ashman EJ, et al. Neurology. 2016; 86:1818-26.

8. Bendtsen L, Sacco S, Ashina M, et al. J Headache Pain. 2018; 19(1):91.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.